Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chunlin Zhou

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Molecular and Clinical Oncology|February 20, 2016
Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapseShuning Wei, Yingchang Mi, Hui Wei, et al.
Molecular Oncology|February 10, 2025
Classification of acute myeloid leukemia based on multi-omics and prognosis prediction valueYang Song, Zhe Wang, Guangji Zhang, et al.
Clinical Therapeutics|June 14, 2021
A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaXiaoyuan Gong, Le Li, Hui Wei, et al.
Haematologica|April 16, 2026
Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patientsAo Zhang, Benfa Gong, Yuntao Liu, et al.
Annals of Hematology|January 13, 2019
Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-upBingcheng Liu, Ying Wang, Chunlin Zhou, et al.
Immunotherapy|August 12, 2020
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell functionShuning Wei, Runxia Gu, Yingxi Xu, et al.
Therapeutics and Clinical Risk Management|February 13, 2024
Treatment Patterns and <i>FLT3</i> Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational StudyBenfa Gong, Li-Jen Cheng, Christopher H Young, et al.
Haematologica|January 18, 2024
A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from ChinaXiaoyuan Gong, Qiuyun Fang, Runxia Gu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 24, 2014
[Optimal treatment of adult Ph negative acute lymphoblastic leukemia]Xingli Zhao, Hui Wei, Dong Lin, et al.
Cancer Science|April 16, 2026
Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized TrialChunlin Zhou, Le Li, Yan Li, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Molecular and Clinical Oncology|February 20, 2016
Cyclophosphamide combined with mitoxantrone and cytarabine is an effective salvage regimen for patients with acute myeloid leukemia who experienced primary induction failure or relapseShuning Wei, Yingchang Mi, Hui Wei, et al.
Molecular Oncology|February 10, 2025
Classification of acute myeloid leukemia based on multi-omics and prognosis prediction valueYang Song, Zhe Wang, Guangji Zhang, et al.
Clinical Therapeutics|June 14, 2021
A Higher Dose of Dasatinib May Increase the Possibility of Crossing the Blood-brain Barrier in the Treatment of Patients With Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaXiaoyuan Gong, Le Li, Hui Wei, et al.
Haematologica|April 16, 2026
Durable deep molecular response via CD19 chimeric antigen receptor T-cell therapy combined with a third-generation tyrosine kinase inhibitor in acute leukemia of ambiguous lineage with the Philadelphia chromosome: a potential strategy for transplant-ineligible patientsAo Zhang, Benfa Gong, Yuntao Liu, et al.
Annals of Hematology|January 13, 2019
Nilotinib combined with multi-agent chemotherapy in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center prospective study with long-term follow-upBingcheng Liu, Ying Wang, Chunlin Zhou, et al.
Immunotherapy|August 12, 2020
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell functionShuning Wei, Runxia Gu, Yingxi Xu, et al.
Therapeutics and Clinical Risk Management|February 13, 2024
Treatment Patterns and <i>FLT3</i> Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational StudyBenfa Gong, Li-Jen Cheng, Christopher H Young, et al.
Haematologica|January 18, 2024
A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from ChinaXiaoyuan Gong, Qiuyun Fang, Runxia Gu, et al.
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|October 24, 2014
[Optimal treatment of adult Ph negative acute lymphoblastic leukemia]Xingli Zhao, Hui Wei, Dong Lin, et al.
Cancer Science|April 16, 2026
Daunorubicin-45 Vs. Daunorubicin-60 for Induction in Intermediate-Age Patients of AML: Results From a Randomized TrialChunlin Zhou, Le Li, Yan Li, et al.
Pageof 7